383 related articles for article (PubMed ID: 25117977)
1. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
Baker GJ; Yadav VN; Motsch S; Koschmann C; Calinescu AA; Mineharu Y; Camelo-Piragua SI; Orringer D; Bannykh S; Nichols WS; deCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Neoplasia; 2014 Jul; 16(7):543-61. PubMed ID: 25117977
[TBL] [Abstract][Full Text] [Related]
2. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
3. Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Mathivet T; Bouleti C; Van Woensel M; Stanchi F; Verschuere T; Phng LK; Dejaegher J; Balcer M; Matsumoto K; Georgieva PB; Belmans J; Sciot R; Stockmann C; Mazzone M; De Vleeschouwer S; Gerhardt H
EMBO Mol Med; 2017 Dec; 9(12):1629-1645. PubMed ID: 29038312
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
6. Invasion as limitation to anti-angiogenic glioma therapy.
Lamszus K; Kunkel P; Westphal M
Acta Neurochir Suppl; 2003; 88():169-77. PubMed ID: 14531575
[TBL] [Abstract][Full Text] [Related]
7. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro.
Shamshiripour P; Rahnama M; Nikoobakht M; Rad VF; Moradi AR; Ahmadvand D
J Control Release; 2024 May; 369():128-145. PubMed ID: 38522817
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.
Wu HB; Yang S; Weng HY; Chen Q; Zhao XL; Fu WJ; Niu Q; Ping YF; Wang JM; Zhang X; Yao XH; Bian XW
Autophagy; 2017 Sep; 13(9):1528-1542. PubMed ID: 28812437
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
12. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
Osterberg N; Ferrara N; Vacher J; Gaedicke S; Niedermann G; Weyerbrock A; Doostkam S; Schaefer HE; Plate KH; Machein MR
Neuro Oncol; 2016 Jul; 18(7):939-49. PubMed ID: 26951383
[TBL] [Abstract][Full Text] [Related]
13. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
[TBL] [Abstract][Full Text] [Related]
14. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
Goldbrunner RH; Bendszus M; Wood J; Kiderlen M; Sasaki M; Tonn JC
Neurosurgery; 2004 Aug; 55(2):426-32; discussion 432. PubMed ID: 15271251
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
[TBL] [Abstract][Full Text] [Related]
17. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.
Park SY; Piao Y; Jeong KJ; Dong J; de Groot JF
Mol Cancer Ther; 2016 Sep; 15(9):2187-97. PubMed ID: 27307601
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-driven glioma growth and vascularization in an orthotopic rat model monitored by magnetic resonance imaging.
Goldbrunner RH; Bendszus M; Sasaki M; Kraemer T; Plate KH; Roosen K; Tonn JC
Neurosurgery; 2000 Oct; 47(4):921-9; discussion 929-30. PubMed ID: 11014432
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
Yadav VN; Zamler D; Baker GJ; Kadiyala P; Erdreich-Epstein A; DeCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Oncotarget; 2016 Dec; 7(50):83701-83719. PubMed ID: 27863376
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
